This is prospective research study which will include patients with recurrent or metastatic squamous cell carcinoma of the head and neck, esophagus and anal canal starting on first-line platinum based chemotherapy or any line of immunotherapy treatment.This study aims to characterize the dynamic changes in genomic, epigenetic, immune profiling and imaging data during treatment with systemic therapy. Patients will have archived tumor samples requested as well as blood samples collected at up to four time points to analyze these changes. Imaging data will be derived from patients' routine CT scans before and after treatment.
Study Type
OBSERVATIONAL
Enrollment
39
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Characterization of Genomic, epigenetic and Immune Profiling Features
To comprehensively characterize genomic, epigenetic and immune profiling features and changes in longitudinal blood samples that are associated with systemic treatment of recurrent or metastatic squamous cell cancers of the head \& neck, esophagus and anal canal.
Time frame: Through study completion, up to 4 years
Establish a Clinically Annotated Biorepository
To establish a clinically annotated biorepository of archived tumor and longitudinal blood samples, with serial radiomic evaluations in patients with recurrent/metastatic squamous cell cancers commencing on any new systemic treatments.
Time frame: Through study completion, up to 4 years
Correlate Multi-Omic Results with Clinical Outcome
To correlate genomic, othr-omic, radiomic and immune profiling results with clinical outcome - to identify potential predictive markers of response/resistance to systemic therapy.
Time frame: Through study completion, up to 4 years
Compare HPV-Positive and HPV-Negative Cell Histologies
To compare HPV-positive and HPV-negative squamous cell histology across three disease sites with multi-omic assessment.
Time frame: Through study completion, up to 4 years
Investigate the Relationship Between Genomic Profiles and Radiomic Signatures
To investigate whether any correlation or relation exists between tumor genomic profiles and radiomic imaging signatures.
Time frame: Through study completion, up to 4 years
Enable Data-Sharing
To enable data sharing with Queen's University Belfast as a collaborative initiative based on this project
Time frame: Though study completion, up to 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.